{
  "docId": "019de073-948a-7043-8b3b-a5ac9bb504f9",
  "docSlug": "d72f38beef66cb68e946399178678a94",
  "documentTitle": "Roivant Sciences | Investor Presentation Deck | 21 slides",
  "authorId": "roivant-sciences",
  "authorName": "Immunovant",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 17,
  "pageCount": 21,
  "prevPage": 16,
  "nextPage": 18,
  "slideType": "comparison_table",
  "function": "compare_peers",
  "density": "balanced",
  "nDataPoints": 12,
  "notes": "The table uses 'X' marks to indicate feature presence and specific clinical trial/dosing status for the Immunovant franchise.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-948a-7043-8b3b-a5ac9bb504f9/17",
  "deckHref": "/decks/019de073-948a-7043-8b3b-a5ac9bb504f9",
  "deckJsonHref": "/decks/019de073-948a-7043-8b3b-a5ac9bb504f9.json",
  "deckAnchorHref": "/decks/019de073-948a-7043-8b3b-a5ac9bb504f9#slide-17",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.7,
        "x": 0.08,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "1. Source: Argenx Corporate Presentation, June 2022; 2. Potential outcomes if Phase 1 results are as predicted by pre-clinical studies in cynomolgus monkeys; 3. Induction refers to starting with saturating dose that can achieve ~80% IgG reduction",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c834df07-8c7a-4cb3-8170-83c461648e82",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.85,
        "x": 0.08,
        "y": 0.2
      },
      "kind": "table",
      "text": "Comparison matrix of product attributes and dosing capabilities across efgartigimod, batoclimab, and IMVT-1402.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ae948c69-8d77-406a-b5c9-fbc05e334767",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Batoclimab and IMVT-1402 have the potential to offer multiple differentiated product features, if approved",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "25d831f6-c716-4460-a105-b648400dc752",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}